Peptide Drug Discovery: A Complete Guide to the Science, History, and Future of Therapeutic Peptides

Research suggests that peptide drug discovery has evolved from a niche area of biochemical research into one of the most dynamic fields in modern pharmaceutical science. Over the last century, scientists have progressed from isolating naturally occurring peptide hormones to designing highly engineered molecules with improved stability, longer duration of action, and greater receptor selectivity.

Today, peptide therapeutics are used in numerous areas of medicine, including endocrinology, oncology, gastroenterology, osteoporosis, cardiovascular disease, and rare genetic disorders. Meanwhile, hundreds of additional peptide candidates continue to move through laboratory research and clinical development.

The story of peptide drug discovery is one of continuous scientific innovation. Advances in chemistry, structural biology, molecular pharmacology, computational modeling, and biotechnology have transformed small chains of amino acids into an important class of therapeutic molecules.

This article explores the history of peptide drug discovery, the technological breakthroughs that made peptide medicines possible, and the scientific advances shaping the future of this rapidly expanding field.

What Is a Peptide?

Peptides are short chains of amino acids linked together by peptide bonds. They are smaller than proteins but often perform equally important biological functions.

Nearly every multicellular organism relies on peptides to coordinate communication between cells.

Scientists have identified thousands of naturally occurring peptides involved in:

Hormone regulation
Cell signaling
Immune function
Appetite regulation
Stress responses
Reproduction
Wound healing
Nervous system communication
Growth and development
Metabolic control

Unlike many small-molecule compounds, peptides often bind with remarkable specificity to receptors located on the surfaces of cells. This precision has made them attractive starting points for pharmaceutical development.

The Birth of Peptide Science

The foundations of peptide drug discovery were established during the late nineteenth and early twentieth centuries.

Scientists first began understanding that proteins consisted of amino acids connected in chains. As analytical chemistry improved, researchers gradually recognized that smaller amino acid chains possessed unique biological activity independent of larger proteins.

By the early 1900s, investigators had identified several peptide hormones that controlled critical physiological processes.

These discoveries transformed endocrinology and introduced an entirely new approach to treating disease by replacing or modifying naturally occurring signaling molecules.

Insulin Changed Modern Medicine

Although insulin is technically a protein rather than a short peptide, its discovery fundamentally influenced peptide therapeutics.

In 1921, Frederick Banting and Charles Best successfully isolated insulin, creating one of medicine’s most significant breakthroughs.

For the first time, patients with diabetes had an effective treatment that dramatically improved survival.

Initially, insulin was extracted from animal pancreases. While lifesaving, these preparations varied in purity and occasionally caused immune reactions.

The eventual development of recombinant human insulin demonstrated that biologically active amino acid sequences could be manufactured with remarkable consistency, laying important groundwork for future peptide drug development.

Discovering Nature’s Chemical Messengers

Following insulin, researchers identified numerous biologically active peptides throughout the body.

Among the most influential discoveries were:

Oxytocin

A peptide involved in reproductive physiology and social behavior.

Vasopressin

An important regulator of blood pressure and water balance.

Glucagon

A peptide hormone that influences glucose regulation.

ACTH

Adrenocorticotropic hormone, which regulates adrenal function.

Calcitonin

A peptide involved in calcium homeostasis and bone metabolism.

Each newly discovered peptide expanded scientists’ understanding of how small amino acid chains regulate complex biological systems.

A Nobel Prize That Changed Peptide Chemistry

One of the defining moments in peptide science occurred in 1953.

Vincent du Vigneaud successfully synthesized oxytocin in the laboratory.

This achievement demonstrated that a biologically active peptide hormone could be created entirely through chemical synthesis rather than isolated from animal tissues.

For this groundbreaking work, du Vigneaud received the Nobel Prize in Chemistry in 1955.

His accomplishment proved that therapeutic peptides could eventually be manufactured at scale, opening entirely new possibilities for pharmaceutical development.

Understanding Why Peptides Matter

Unlike traditional chemical drugs, peptides often mimic naturally occurring signaling molecules.

Instead of broadly affecting multiple biological systems, many peptides interact with a single receptor or a closely related group of receptors.

This selectivity offers several potential advantages during drug development:

Greater receptor specificity
Reduced off-target interactions
Predictable biological activity
High potency
Natural compatibility with biological pathways
Opportunities for rational molecular design

Researchers quickly realized these characteristics could make peptides useful tools for treating diseases caused by missing, deficient, or dysfunctional signaling molecules.

The Challenge of Natural Peptides

Despite their promise, naturally occurring peptides presented major obstacles.

Scientists discovered that most peptides:

Break down rapidly in the bloodstream
Are easily degraded by digestive enzymes
Often require injection
Have relatively short half-lives
Can be difficult to manufacture consistently
May lose activity during storage

Early peptide medicines therefore required frequent dosing, limiting convenience and commercial viability.

These challenges inspired decades of research focused on improving peptide stability without sacrificing biological activity.

Bruce Merrifield Revolutionized Peptide Manufacturing

One of the greatest breakthroughs in peptide chemistry occurred in 1963.

Bruce Merrifield introduced Solid-Phase Peptide Synthesis (SPPS).

Rather than synthesizing peptides entirely in solution, Merrifield attached the growing amino acid chain to a solid resin bead.

Each amino acid could then be added one step at a time while impurities were washed away after every reaction.

The advantages were extraordinary.

Scientists could now produce peptides:

Faster
More accurately
With greater purity
In larger quantities
Using automated equipment

SPPS rapidly became the global standard for peptide production.

Nearly every research laboratory and pharmaceutical manufacturer developing peptide therapeutics continues to use variations of Merrifield’s original technique.

His invention earned the Nobel Prize in Chemistry in 1984 and remains one of the most influential technological advances in modern medicinal chemistry.

The Expansion of Therapeutic Peptide Research

During the 1970s and 1980s, peptide drug discovery accelerated dramatically.

Scientists began identifying peptide receptors throughout nearly every organ system.

Research expanded into:

Metabolism
Neurology
Reproductive biology
Cardiovascular physiology
Gastrointestinal hormones
Immunology
Growth regulation
Pain signaling

Advances in receptor biology allowed researchers to understand precisely how peptide hormones interacted with cells.

Instead of relying solely on naturally occurring molecules, scientists started designing modified peptides with improved pharmaceutical properties.

This represented the beginning of modern peptide engineering.

From Natural Hormones to Engineered Medicines

The first generation of peptide therapeutics closely resembled naturally occurring hormones.

However, researchers soon realized that even minor molecular modifications could dramatically improve performance.

Examples included replacing individual amino acids, protecting vulnerable regions of the peptide chain, or altering the molecule’s three-dimensional shape.

These changes helped researchers create peptides that:

Lasted longer in circulation
Bound receptors more selectively
Resisted enzymatic degradation
Required less frequent administration
Improved manufacturing consistency

Rather than simply copying nature, pharmaceutical scientists began improving upon it.

Biotechnology Accelerates Innovation

The biotechnology revolution of the 1980s and 1990s introduced entirely new tools for peptide discovery.

Researchers gained access to technologies including:

Recombinant DNA engineering
Automated amino acid synthesizers
High-performance liquid chromatography (HPLC)
Mass spectrometry
Computer-assisted molecular modeling
Advanced structural biology

Each innovation allowed scientists to better understand peptide structure and function while producing increasingly sophisticated therapeutic candidates.

Drug discovery timelines gradually shortened as laboratory techniques became faster and more reliable.

Why Peptide Therapeutics Continue to Expand

Today, peptides occupy a unique position between traditional small-molecule drugs and larger biologic therapies such as monoclonal antibodies.

They combine several attractive characteristics.

Many peptides exhibit:

High biological specificity
Strong receptor affinity
Predictable metabolism
Flexible molecular engineering
Relatively straightforward synthesis
Excellent compatibility with computational drug design

These advantages explain why peptide therapeutics continue to represent one of the fastest-growing areas of pharmaceutical research.

However, every successful peptide medicine reflects years of optimization involving chemistry, pharmacology, toxicology, manufacturing, and clinical evaluation.

Peptide Drug Discovery: A Complete Guide to the Science, History, and Future of Therapeutic Peptides

Modern Peptide Engineering: Designing Better Therapeutics

By the late twentieth century, researchers had solved many of the manufacturing challenges associated with peptide production. The next objective was improving how peptides behaved inside the body.

Naturally occurring peptides are often cleared quickly from circulation. Many are susceptible to enzymatic degradation, limiting how long they remain biologically active. Pharmaceutical scientists therefore began engineering peptide analogs that retained their desired receptor activity while improving pharmacokinetic properties.

Several strategies became central to modern peptide design.

Amino Acid Substitution

Replacing one or more naturally occurring amino acids with synthetic or modified amino acids can increase resistance to enzymatic degradation while maintaining receptor affinity.

Even a single amino acid substitution may significantly improve stability or alter receptor selectivity.

Cyclization

Cyclization joins portions of the peptide into a ring structure.

Cyclic peptides generally:

Resist enzymatic breakdown
Maintain structural stability
Display improved receptor binding
Often exhibit longer biological activity

Many naturally occurring peptides are already cyclic, inspiring researchers to develop synthetic cyclic analogs.

PEGylation

Attaching polyethylene glycol (PEG) molecules to peptides can:

Increase molecular size
Slow kidney clearance
Improve circulation time
Reduce dosing frequency

Although PEGylation is not appropriate for every peptide, it represented one of the earliest successful methods for extending peptide half-life.

Lipidation

Attaching fatty acid chains allows peptides to bind circulating albumin.

Because albumin remains in the bloodstream much longer than many peptides, this strategy substantially extends biological activity.

Several modern peptide medicines use lipidation to reduce injection frequency.

Fusion Technologies

Scientists have also combined peptides with larger proteins or antibody fragments.

These hybrid molecules may improve:

Stability
Tissue distribution
Circulation time
Manufacturing consistency

Each engineering approach reflects decades of research aimed at overcoming the natural limitations of peptide molecules.

FDA-Approved Peptide Therapeutics

Although hundreds of peptide candidates remain under investigation, numerous peptide medicines have already received regulatory approval.

These therapies span multiple medical specialties.

Endocrinology

Endocrinology remains the largest therapeutic area for peptide medicines.

Examples include:

Insulin analogs
GLP-1 receptor agonists
Growth hormone–related peptides
Calcitonin analogs

These medicines illustrate how modifying naturally occurring hormones can improve therapeutic performance.

Oncology

Several peptide-based agents are used in cancer diagnosis and treatment.

Researchers have also developed peptide radiopharmaceuticals capable of delivering radioactive isotopes to specific tissues by targeting peptide receptors expressed on tumor cells.

Gastroenterology

Peptides regulating gastrointestinal hormones continue to be studied and developed for disorders involving digestion, secretion, and metabolic regulation.

Bone Health

Peptide analogs affecting calcium metabolism have contributed to therapies for osteoporosis and related skeletal disorders.

Rare Diseases

Certain rare inherited disorders have benefited from peptide therapeutics that replace deficient biological signaling molecules or regulate specific metabolic pathways.

The GLP-1 Revolution

One of the most influential developments in peptide therapeutics has been the evolution of glucagon-like peptide-1 (GLP-1) receptor agonists.

Native GLP-1 is rapidly degraded by enzymes, making it impractical as a medicine without modification.

Researchers overcame this limitation through extensive molecular engineering.

Successive generations of GLP-1 analogs incorporated:

Improved receptor affinity
Greater enzymatic stability
Albumin binding
Extended half-life
Reduced injection frequency

These advances demonstrate how medicinal chemistry can transform a short-lived endogenous peptide into a clinically useful pharmaceutical.

Current research also explores multi-receptor peptide agonists designed to interact with more than one signaling pathway simultaneously.

Beyond Hormones

Although hormones remain central to peptide therapeutics, researchers now investigate peptides involved in numerous biological systems.

Current areas of interest include:

Immune signaling
Antimicrobial peptides
Fibrosis pathways
Cardiovascular regulation
Mitochondrial biology
Neurological signaling
Tissue remodeling
Cellular aging
Regenerative biology

Every newly identified peptide signaling pathway creates opportunities for additional laboratory investigation.

Artificial Intelligence Is Reshaping Peptide Discovery

Artificial intelligence has become an increasingly valuable component of peptide research.

Rather than replacing laboratory science, machine learning helps researchers identify the most promising peptide candidates before synthesis begins.

Modern computational models can estimate:

Three-dimensional structure
Receptor interactions
Stability
Solubility
Toxicity risk
Binding affinity
Sequence optimization

This significantly reduces the number of molecules that must be synthesized experimentally.

AI-assisted drug discovery is expected to become increasingly important as peptide libraries continue expanding.

High-Throughput Screening

Automation has transformed peptide discovery.

Researchers can now evaluate thousands—or even millions—of peptide variants using robotic screening systems.

Laboratories routinely assess:

Biological activity
Selectivity
Stability
Manufacturing feasibility
Solubility
Safety signals

Candidates showing favorable characteristics advance to additional laboratory studies, while less promising molecules are eliminated early.

This greatly accelerates discovery compared with traditional sequential testing.

Analytical Technologies Behind Peptide Development

Every investigational peptide undergoes extensive analytical characterization before advancing through development.

Common analytical methods include:

High-Performance Liquid Chromatography (HPLC)

HPLC separates peptide molecules and helps determine purity.

Liquid Chromatography–Mass Spectrometry (LC-MS)

LC-MS confirms molecular identity and detects impurities with high sensitivity.

Nuclear Magnetic Resonance (NMR)

NMR provides structural information regarding molecular conformation.

Amino Acid Analysis

Researchers verify peptide composition and sequence.

Stability Testing

Peptides are evaluated under multiple storage conditions to understand degradation pathways and shelf-life characteristics.

These analytical tools help ensure consistency throughout pharmaceutical development.

Manufacturing Has Advanced Dramatically

Modern peptide manufacturing differs substantially from early production methods.

Today’s manufacturers emphasize:

Automated synthesis
Closed production systems
Advanced purification
Strict quality control
Scalable manufacturing
Regulatory compliance

Continuous improvements have reduced production costs while improving consistency and reproducibility.

Challenges Still Facing Peptide Drug Discovery

Despite remarkable progress, several obstacles remain.

Researchers continue working to improve:

Oral peptide delivery
Blood-brain barrier penetration
Intracellular targeting
Manufacturing costs
Long-term stability
Controlled release systems

Each challenge represents an active area of pharmaceutical innovation.

Future Directions

The next generation of peptide therapeutics may include:

Oral peptide medicines
Cell-specific targeting systems
Personalized peptide therapies
Smart delivery nanoparticles
Multi-functional peptide constructs
AI-designed peptide libraries
Precision receptor engineering
Longer-acting peptide analogs

As structural biology, computational chemistry, and biotechnology continue advancing, scientists are expected to identify additional peptide targets that were previously inaccessible.

Research Peptides Versus Approved Medicines

It is important to distinguish between approved peptide medications and research peptides.

Approved peptide medicines have undergone years of laboratory investigation, toxicology studies, clinical trials, manufacturing validation, and regulatory review before becoming available for patient care.

Research peptides are intended exclusively for scientific investigation. Their biological characteristics, safety profiles, and potential applications may still be under evaluation, and they should not be interpreted as approved medical treatments.

Understanding this distinction helps ensure accurate interpretation of peptide research and responsible scientific communication.

Conclusion

The history of peptide drug discovery reflects more than a century of scientific progress. From the first peptide hormones isolated in the early twentieth century to today’s sophisticated engineered analogs, peptide therapeutics have become one of the most innovative areas of pharmaceutical research.

Breakthroughs such as solid-phase peptide synthesis, recombinant biotechnology, advanced analytical chemistry, and artificial intelligence have dramatically expanded what researchers can accomplish. These advances continue to improve how peptides are designed, manufactured, characterized, and evaluated.

Although only a fraction of investigational peptides ultimately become approved medicines, ongoing research continues to deepen our understanding of cellular communication and molecular pharmacology. As peptide engineering technologies evolve, researchers are likely to uncover new opportunities for highly targeted therapeutics capable of addressing increasingly complex biological pathways.

Learn More About Research Peptides

HealthLab Peptides offers a catalog of research-use-only (RUO) peptide products intended exclusively for qualified laboratory research.

Explore additional research compounds:

Frequently Asked Questions

What is peptide drug discovery?

Peptide drug discovery is the scientific process of identifying, designing, optimizing, manufacturing, and evaluating peptide molecules that may eventually become pharmaceutical therapies.

Why are peptides useful in medicine?

Many peptides naturally interact with highly specific cellular receptors, making them valuable starting points for developing targeted therapeutic agents.

What was the biggest breakthrough in peptide chemistry?

The invention of solid-phase peptide synthesis by Bruce Merrifield revolutionized peptide manufacturing and remains the foundation of modern peptide production.

Can peptides be taken orally?

Most peptide medicines are administered by injection because digestive enzymes rapidly degrade many peptides. Researchers continue developing oral peptide delivery technologies.

How does artificial intelligence assist peptide discovery?

AI helps researchers predict molecular structure, optimize amino acid sequences, estimate receptor interactions, and prioritize promising candidates for laboratory testing.

References

Merrifield RB. Solid Phase Peptide Synthesis. Journal of the American Chemical Society. 1963.
Fosgerau K, Hoffmann T. Peptide Therapeutics: Current Status and Future Directions. Drug Discovery Today. 2015.
Lau JL, Dunn MK. Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions. Bioorganic & Medicinal Chemistry. 2018.
Craik DJ, Fairlie DP, Liras S, Price D. The Future of Peptide-Based Drugs. Chemical Biology & Drug Design. 2013.
Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in Peptide Drug Discovery. Nature Reviews Drug Discovery. 2021.
Di L. Strategic Approaches to Optimizing Peptide ADME Properties. AAPS Journal. 2015.

Research Use Only (RUO) Disclaimer

Products available from HealthLab Peptides are intended solely for laboratory and scientific research by qualified professionals. They are not for human or veterinary use and are not intended to diagnose, treat, cure, or prevent any disease. Statements regarding research compounds have not been evaluated by the U.S. Food and Drug Administration. HealthLab Peptides makes no medical or therapeutic claims regarding its products.

Great. Below are additional sections you can append to the existing article to turn it into a true cornerstone resource.

Timeline of Peptide Drug Discovery

The history of peptide drug discovery spans more than a century. Scientific advances in chemistry, molecular biology, biotechnology, and pharmaceutical manufacturing have steadily expanded the role of peptides in medicine and laboratory research.

Year	Milestone
1901	Emil Fischer develops foundational concepts of peptide chemistry.
1921	Frederick Banting and Charles Best isolate insulin, transforming diabetes treatment.
1953	Vincent du Vigneaud chemically synthesizes oxytocin, proving peptide hormones can be manufactured.
1955	Nobel Prize awarded to du Vigneaud for peptide synthesis.
1963	Bruce Merrifield introduces Solid-Phase Peptide Synthesis (SPPS).
1984	Merrifield receives the Nobel Prize in Chemistry.
1980s	Recombinant biotechnology accelerates peptide manufacturing.
1990s	Improved analytical chemistry increases peptide purity and quality control.
2000s	Long-acting peptide analogs become increasingly common.
2010s	Growth in GLP-1 receptor agonists and peptide engineering.
2020s	Artificial intelligence and computational biology accelerate peptide discovery.

From Laboratory Discovery to an Approved Medicine

Every successful peptide medicine begins with years of laboratory investigation.

The development process is long, expensive, and highly regulated.

1. Target Identification

Researchers first identify a biological pathway involved in disease.

Potential targets include:

Cell receptors
Hormones
Enzymes
Growth factors
Immune signaling molecules

2. Peptide Design

Scientists create candidate peptide sequences capable of interacting with the selected biological target.

Modern design combines:

Structural biology
Medicinal chemistry
Computational modeling
Artificial intelligence
Molecular dynamics simulations

3. Laboratory Testing

Candidate peptides undergo extensive laboratory evaluation.

Scientists study:

Binding affinity
Biological activity
Stability
Solubility
Toxicity signals
Manufacturing feasibility

Only a small percentage of molecules advance.

4. Preclinical Studies

Researchers evaluate promising compounds in preclinical models before requesting authorization for human clinical trials.

These studies examine:

Pharmacokinetics
Pharmacodynamics
Toxicology
Safety margins
Dose selection

5. Clinical Trials

If regulatory agencies approve an investigational application, clinical testing begins.

Phase I

Safety and dosing.

Phase II

Early effectiveness and dose optimization.

Phase III

Large-scale comparison with existing therapies or placebo.

6. Regulatory Review

National regulatory agencies evaluate:

Safety
Manufacturing quality
Clinical evidence
Risk-benefit profile

Only after successful review can a medicine receive approval.

Why Most Peptide Drug Candidates Never Reach the Market

Although peptide research is expanding rapidly, relatively few investigational molecules become approved medicines.

Scientists encounter numerous challenges.

Poor Stability

Many peptides degrade within minutes after administration.

Limited Oral Absorption

Digestive enzymes rapidly break down peptide molecules.

This explains why many peptide medicines require injection.

Manufacturing Complexity

Long peptides become increasingly difficult to manufacture with high purity.

Biological Complexity

Excellent laboratory performance does not always translate into clinical success.

Commercial Considerations

Some promising molecules are discontinued because manufacturing costs exceed potential commercial value.

Peptides vs Small Molecules vs Antibodies

Feature	Peptides	Small Molecules	Monoclonal Antibodies
Molecular Size	Medium	Small	Large
Target Specificity	High	Moderate	Very High
Oral Availability	Usually Limited	Often Good	No
Manufacturing	Moderate	Easier	Complex
Half-Life	Variable	Variable	Long
Tissue Penetration	Moderate	Excellent	Limited

Each therapeutic class occupies an important role in pharmaceutical development.

Artificial Intelligence Is Accelerating Peptide Discovery

One of the most exciting developments involves AI-assisted molecular design.

Researchers now use machine learning to predict:

Protein folding
Receptor interactions
Peptide stability
Toxicity risk
Amino acid optimization
Manufacturing efficiency

Instead of experimentally synthesizing thousands of random peptides, AI helps identify the most promising candidates before laboratory work begins.

This reduces both time and development costs.

Personalized Peptide Medicine

Precision medicine may eventually influence peptide therapeutics.

Future research may allow scientists to design peptide therapies tailored to:

Individual genetics
Tumor biology
Immune profiles
Metabolic characteristics
Biomarker expression

Although much work remains, personalized peptide medicine represents an exciting area of ongoing investigation.

Emerging Technologies

Researchers continue exploring innovative peptide delivery systems.

These include:

Oral Peptides

Scientists are developing protective formulations capable of surviving the digestive tract.

Nasal Delivery

Certain peptides demonstrate potential for intranasal administration, particularly for research involving central nervous system pathways.

Microneedle Systems

Microneedle patches may improve convenience while reducing discomfort associated with injections.

Nanoparticle Delivery

Nanotechnology may eventually improve tissue targeting while protecting peptides from degradation.

Smart Drug Delivery

Researchers are investigating delivery systems capable of releasing peptides only under specific biological conditions.

Current Areas of Active Peptide Research

Peptide discovery now spans nearly every area of biomedical science.

Scientists continue investigating peptides related to:

Endocrinology
Oncology
Cardiovascular biology
Kidney disease
Liver disease
Neurology
Fibrosis
Autoimmune disorders
Infectious disease
Metabolism
Healthy aging
Tissue regeneration
Mitochondrial biology
Cell signaling

Each year, newly identified peptide pathways expand opportunities for future research.

Frequently Asked Questions

How many peptide drugs have been approved?

Dozens of peptide-based medicines have received approval worldwide, with additional candidates progressing through clinical development. The exact number changes as new therapies are approved in different jurisdictions.

Why are peptides attractive drug candidates?

Peptides often bind highly specific biological receptors, allowing researchers to design therapies that target particular signaling pathways with precision.

Why can’t most peptide drugs be taken by mouth?

Digestive enzymes rapidly break down many peptide molecules before they reach the bloodstream. Researchers continue investigating oral formulations to overcome this limitation.

What is Solid-Phase Peptide Synthesis?

Solid-Phase Peptide Synthesis (SPPS), developed by Bruce Merrifield in 1963, is the foundation of modern peptide manufacturing. It enables amino acids to be assembled sequentially on a solid support, improving efficiency and purity.

How long does it take to develop a peptide drug?

From early discovery through regulatory approval, development commonly takes 10–15 years or longer. Many candidates do not advance beyond preclinical or early clinical stages.

Are research peptides the same as approved medications?

No. Research peptides are intended for scientific investigation and may still be undergoing laboratory evaluation. Approved peptide medicines have completed extensive testing and regulatory review.

Final Thoughts

The progress of peptide drug discovery demonstrates how advances in chemistry, biology, engineering, and computational science can converge to create new therapeutic possibilities. From the earliest peptide hormones to today’s engineered analogs, the field has evolved into one of the most active areas of pharmaceutical innovation.

As artificial intelligence, precision medicine, and advanced manufacturing continue to mature, peptide science is expected to remain at the forefront of biomedical research for years to come.